Informed by nature
and guided by science
Informed
by nature
and guided
by science
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Bringing together leaders in the business of medicine and science
Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Our News
Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care
The agreement expands on an existing partnership and grants Psyence the right to commercialize Filament’s natural psilocybin drug candidate PEX010 25mg within palliative care
Psyence Group Announces Closing Of Second Tranche Of Private Placement And Appointment Of Strategic Advisor
Psyence Group Announces Closing Of Second Tranche Of Private [...]
GOODMIND Available For Sale In The United Kingdom And Europe – Exclusive Distribution Agreement Concluded With This Works.
Psyence is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products Limited (“This Works”) for the distribution and sale of the joint venture’s functional mushroom brand, GOODMINDTM, in the United Kingdom and Europe.